Sponsor & Developer Portfolio

Merck

Clinical development pipeline, platform architecture, and registered trial tracking for Merck vaccine candidates.

Candidates

Target Diseases

Linked Studies

Development Phase Distribution

Discontinued / Inactive: 15 Phase 1 Clinical Trial: 6 Phase 3 Clinical Trial: 3 Phase 2 Clinical Trial: 1

Platform Technologies

Biological (unspecified platform): 22 Protein / subunit: 1 Inactivated: 1 mRNA: 1

Target Pathogens & Indications

COVID-19 Dengue HIV HPV Healthy Healthy Participants Measles / Mumps / Rubella Neoplasms Non-Small Cell Lung Cancer Papillomavirus Infections Pneumococcal disease Rotavirus Sarcoma Synovial Sarcoma Tuberculosis Varicella / Zoster

Vaccine Pipeline Candidates (25)

Detailed candidate profiles, clinical phases, target indications, and anticipated milestones.

View Global Pipeline Matrix →

Discontinued / Inactive ctgov-cmb305-immune-design-a-subsidiary-of-merck-co-inc-rahway-new-jer

CMB305

Target: Sarcoma

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2019-02-06 (registry estimate)

View Full Clinical Profile →

Discontinued / Inactive ctgov-comparator-rotateq-merck-sharp-dohme-llc

Comparator: RotaTeq

Target: Rotavirus

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2010-01 (registry estimate)

View Full Clinical Profile → Disease Hub →

Discontinued / Inactive ctgov-lv305-immune-design-a-subsidiary-of-merck-co-inc-rahway-new-jers

G305

Target: Synovial Sarcoma

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2018-11-20 (registry estimate)

View Full Clinical Profile →

Discontinued / Inactive ctgov-varivax-vep-merck-sharp-dohme-llc

M-M-R™ II

Target: Varicella / Zoster

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2015-10 (registry estimate)

View Full Clinical Profile → Disease Hub →

Discontinued / Inactive ctgov-measles-mumps-rubella-and-varicella-oka-merck-virus-vaccine-live

M-M-R™ II and Varivax™

Target: Measles / Mumps / Rubella

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2008-05 (registry estimate)

View Full Clinical Profile → Disease Hub →

Discontinued / Inactive ctgov-mrkad5-hiv-1-gag-pol-nef-4-x-10-9-ad5-vg-dose-v520-merck-sharp-d

MRKAd5 HIV-1 gag/pol/nef 4 x 10^9 Ad5 vg/dose (V520)

Target: HIV

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2008-05 (registry estimate)

View Full Clinical Profile →

Discontinued / Inactive ctgov-quadrivalent-human-papillomavirus-types-6-11-16-18-recombinant-v

Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine

Target: HPV

Platform: Protein / subunit

Key Milestone: Primary completion (most advanced trial): 2013-10-01 (registry estimate)

View Full Clinical Profile → Disease Hub →

Discontinued / Inactive ctgov-rotavirus-vaccine-live-oral-pentavalent-merck-sharp-dohme-llc

Rotavirus Vaccine, Live, Oral, Pentavalent

Target: Rotavirus

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2010-08 (registry estimate)

View Full Clinical Profile → Disease Hub →

Discontinued / Inactive ctgov-tecemotide-merck-kgaa-darmstadt-germany

Tecemotide

Target: Non-Small Cell Lung Cancer

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2015-06 (registry estimate)

View Full Clinical Profile →

Discontinued / Inactive ctgov-trivalent-mrkad5-hiv-1-gag-pol-nef-1-5x10-10-ad-vg-dose-merck-sh

Trivalent MRKAd5 HIV-1 gag/pol/nef (1.5x10^10 ad-vg/dose)

Target: HIV

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2007-09 (registry estimate)

View Full Clinical Profile →

Discontinued / Inactive ctgov-v212-lot-1-merck-sharp-dohme-llc

V212 Lot 1

Target: Varicella / Zoster

Platform: Inactivated

Key Milestone: Primary completion (most advanced trial): 2015-03 (registry estimate)

View Full Clinical Profile → Disease Hub →

Discontinued / Inactive ctgov-v502-merck-sharp-dohme-llc

V502

Target: HPV

Platform: Biological (unspecified platform)

Key Milestone: See linked ClinicalTrials.gov records for primary completion dates

View Full Clinical Profile → Disease Hub →

Discontinued / Inactive ctgov-v590-merck-sharp-dohme-llc

V590

Target: COVID-19

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2021-02-18 (registry estimate)

View Full Clinical Profile → Disease Hub →

Discontinued / Inactive ctgov-v591-merck-sharp-dohme-llc

V591

Target: COVID-19

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2021-03-05 (registry estimate)

View Full Clinical Profile → Disease Hub →

Discontinued / Inactive ctgov-v941-merck-sharp-dohme-llc

V941

Target: Neoplasms

Platform: mRNA

Key Milestone: Primary completion (most advanced trial): 2022-08-25 (registry estimate)

View Full Clinical Profile →

Phase 1 Clinical Trial ctgov-fluzone-hd-influenza-vaccine-cidara-therapeutics-inc-a-subsidiar

Fluzone HD influenza vaccine

Target: Healthy Participants

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2026-12 (registry estimate)

View Full Clinical Profile → Disease Hub →

Phase 1 Clinical Trial ctgov-v118c-stage-1-merck-sharp-dohme-llc

V118C (Stage 1)

Target: Pneumococcal disease

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2028-10-24 (registry estimate)

View Full Clinical Profile → Disease Hub →

Phase 1 Clinical Trial ctgov-v118e-merck-sharp-dohme-llc

V118E

Target: Healthy

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2027-11-12 (registry estimate)

View Full Clinical Profile →

Phase 1 Clinical Trial ctgov-v350a-merck-sharp-dohme-llc

V350A

Target: Healthy

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2028-07-17 (registry estimate)

View Full Clinical Profile →

Phase 1 Clinical Trial ctgov-gardasil-9-g9-merck-sharp-dohme-llc

V540B

Target: Healthy

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2026-11-20 (registry estimate)

View Full Clinical Profile →

Phase 1 Clinical Trial ctgov-v540d-merck-sharp-dohme-llc

V540D

Target: Healthy

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2026-11-30 (registry estimate)

View Full Clinical Profile →

Phase 2 Clinical Trial ctgov-v540a-2-merck-sharp-dohme-llc

V540A-2

Target: Healthy

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2028-04-04 (registry estimate)

View Full Clinical Profile →

Phase 3 Clinical Trial ctgov-9vhpv-vaccine-merck-sharp-dohme-llc

9vHPV vaccine

Target: Papillomavirus Infections

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2029-08-03 (registry estimate)

View Full Clinical Profile → Disease Hub →

Phase 3 Clinical Trial ctgov-pembrolizumab-merck-sharp-dohme-llc

BCG

Target: Tuberculosis

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2026-07-31 (registry estimate)

View Full Clinical Profile →

Phase 3 Clinical Trial ctgov-v181-merck-sharp-dohme-llc

V181

Target: Dengue

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2031-10-24 (registry estimate)

View Full Clinical Profile →

Explore Other Vaccine Developers & Sponsors

Compare pipeline volume, phase progression, and modalities across global biopharmaceutical manufacturers.

View All Vaccine Developers →